The settlement will delay the launch of Amgen’s biosimilar until Jan. 31, 2023, and ends all pending patent litigation between the two drugmakers. Abbvie will also be entitled to royalties on sales of Amgen’s biosimilar.
Amgen was the first drugmaker to earn regulatory approval for a Humira biosimilar in Sept. 2016, but refrained from selling the drug during the ongoing patent litigation.
Humira is the highest-selling prescription drug in the world, according to Reuters. The drug generated $4.7 billion in global sales in the second quarter and is on track to exceed $18 billion in annual sales this year. Several other drug companies are still in litigation with Abbvie over their own biosimilar versions of Humira.
More articles on supply chain:
AmerisourceBergen fined $260M over cancer drug packaging: 4 things to know
Millennials least likely to comply with recall notices, study finds
A proactive approach to drug shortages: 6 strategies from Advocate Health Care’s director of central service pharmacy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
